Editas PUBLIC | NASDAQ:EDIT Building the leading genome editing company dedicated to treating patients with genetically defined diseases. https://editasmedicine.com Press Releases Allergan And Editas Medicine Announce Dosing Of First Patient In Landmark Phase 1/2 Clinical Trial Of CRISPR Medicine AGN-151587 (EDIT-101) For The Treatment Of LCA10 Mar 4, 2020 Editas Medicine And Sandhill Therapeutics, Inc. Announce Collaboration To Develop Engineered Cell Medicines To Treat Cancer Jan 13, 2020 Editas Medicine Strengthens Executive Leadership Team To Support Long-Term Growth Jan 9, 2020 Editas Medicine Announces In Vivo Proof-Of-Concept Data For EDIT-301, In Development For The Treatment Of Sickle Cell Disease And Beta-Thalassemia Dec 9, 2019 Editas Medicine and Celgene Corp Amend Existing Collaboration Nov 12, 2019 Editas Medicine Appoints Judith R. Abrams, M.D., as CMO Oct 28, 2019 Editas Medicine and AskBio Enter Strategic Research Collaboration Oct 15, 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement Oct 7, 2019 Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer Aug 6, 2019 Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 Jul 25, 2019 « Older Entries Press Coverage Editas Medicine: A Good Proxy For The Gene Editing Space Sep 3, 2019
Allergan And Editas Medicine Announce Dosing Of First Patient In Landmark Phase 1/2 Clinical Trial Of CRISPR Medicine AGN-151587 (EDIT-101) For The Treatment Of LCA10 Mar 4, 2020
Editas Medicine And Sandhill Therapeutics, Inc. Announce Collaboration To Develop Engineered Cell Medicines To Treat Cancer Jan 13, 2020
Editas Medicine Announces In Vivo Proof-Of-Concept Data For EDIT-301, In Development For The Treatment Of Sickle Cell Disease And Beta-Thalassemia Dec 9, 2019
Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 Jul 25, 2019
